Thalomid (Celgene) successful treatment of cough associated with IPF
On September 18, 2012, a new study published in the Annals of Internal Medicine found thalidomide (Thalomid) from Celgene was effective in treating coughing associated with Idiopathic Pulmonary Fibrosis (IPF), a debilitating disease characterized by the scarring or thickening of tissues deep in the lung. A 24 patient trial showed that Thalomid decreased cough by 65% and improved cough specific and respiratory specific quality of life by 20%. Further research is needed to demonstrate the efficacy of thalidomide as a treatment of IPF.
see "Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis: A Randomized Trial"-Maureen R. Horton, MD; Victoria Santopietro; Leena Mathew, BS; Karen M. Horton, MD; Albert J. Polito, MD; Mark C. Liu, MD; Sonye K. Danoff, MD; and Noah Lechtzin, MD -Ann Intern Med. 18 September 2012;157(6):398-406 .
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins